Tech Company Financing Transactions
Nvasc Funding Round
Foundation Fighting Blindness and Retinal Degeneration participated in a venture round for Nvasc. The funding round was announced on 10/16/2023.
Transaction Overview
Company Name
Announced On
10/16/2023
Transaction Type
Amount
Unknown
Round
Undisclosed
Proceeds Purpose
NVasc is developing a therapeutic angiogenesis strategy for the treatment of retinal ischemia associated with the continuum of age-related macular degeneration.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
77 Magnolia Dr
Atherton, CA 94027
USA
Atherton, CA 94027
USA
Phone
Undisclosed
Email Address
Overview
NVasc is an early-stage ophthalmology company with a focus on treating blindness. Operator of an early-stage ophthalmology company intended to focus on treating blindness. The company focuses on treating the leading causes of blindness through choroidal and retinal revascularization as well as has acquired the research rights to growth factors that have been shown to encourage the growth of non-leaking new vessels in the retina and choroid in mouse models of ischemic eye diseases, enabling healthcare sector to get improved treatments.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steven Bettis
Co-Founder
Napoleone Ferrara
Browse more venture capital transactions:
Prev: 10/16/2023: Aronora venture capital transaction
Next: 10/17/2023: Nova Credit venture capital transaction
Share this article
About Database of VC Transactions
We document every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs